MarketPulse
I

$INO

52 articles found
0 positive
52 negative
0 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Legal Action Filed Against Enphase Energy Over Inventory, Tax Credit Claims

Rosen Law Firm sues Enphase Energy for allegedly misrepresenting inventory management and overstating financial outlook regarding tax credit impacts.
ARDTENPHINOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Pharmaceuticals Faces Securities Class Action Over Device, Regulatory Claims

Inovio Pharmaceuticals faces securities lawsuit alleging false statements about its CELLECTRA device and regulatory prospects. Investors who purchased stock between October 2023-December 2025 may qualify for compensation.
INOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Urges Inovio Investors to Act Before Class Action Deadline

Rosen Law Firm files class action lawsuit against Inovio Pharmaceuticals for allegedly misrepresenting manufacturing capabilities and overstating product development prospects, urging investors to act before deadline.
ENPHINOPOMsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

PomDoctor Ltd. Securities Lawsuit Deadline Approaches for Affected Investors

Rosen Law Firm sues PomDoctor Ltd. for stock promotion fraud and misleading statements. Investors must act by April 7, 2026 deadline to join the class action.
ENPHINOPOMsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Inovio Over Alleged Misstatements on Device Manufacturing and Regulatory Plans

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··The Schall Law Firm

Schall Law Firm Opens Class Action Against Inovio Over Manufacturing Claims

Schall Law Firm launches class action against Inovio Pharmaceuticals for alleged misrepresentations about manufacturing capabilities and regulatory timelines. Investors can join until April 7, 2026.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Pharmaceuticals Faces Securities Class Action Over Manufacturing and Regulatory Claims

Rosen Law Firm sues Inovio Pharmaceuticals for allegedly making false statements about manufacturing capabilities and regulatory timelines, causing investor losses through inflated stock prices.
INOsecurities class actionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Endeavor Group Holdings Faces Securities Class Action Over Merger Disclosures

Endeavor Group Holdings faces securities lawsuit over alleged false merger disclosures regarding share valuation, executive pay, and conflicts of interest. Lead plaintiff deadline: March 18, 2026.
BRBRINOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Plug Power Investors Urged to Act Before Class Action Deadline

Rosen Law Firm filed a securities class action against Plug Power for alleged false statements about DOE funding and hydrogen facility construction. April 3, 2026 deadline for claimants.
KDPLUGINOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Inovio Pharmaceuticals

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Inovio Pharmaceuticals Faces Securities Class Action; Investor Deadline Set for April 2026

Inovio Pharmaceuticals faces securities lawsuit over false statements about manufacturing and regulatory prospects. FDA rejected accelerated approval for lead drug candidate, causing 24% stock drop.
INOsecurities class actionFDA rejection
GlobeNewswire Inc.GlobeNewswire Inc.··Robbins Llp

Inovio Pharmaceuticals Faces Class Action Over Device Manufacturing Disclosures

Inovio Pharmaceuticals faces class action lawsuit for allegedly misleading investors about device manufacturing capabilities and regulatory delays, leading to 24% stock decline.
INOsecurities fraudclass action lawsuit